OAM
ADMS

Oxford Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Oxford Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-218,701
Closed -$829K – 1587
2019
Q4 		$829K Buy
218,701
+31,908
+17% +$153K 0.02% 973
2019
Q3 		$955K Buy
+186,793
New +$1.15M 0.02% 968
2018
Q4 		– Sell
-49,336
Closed -$968K – 2217
2018
Q3 		$968K Buy
49,336
+21,170
+75% +$497K 0.02% 1026
2018
Q2 		$723K Buy
+28,166
New +$780K 0.01% 1196

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oxford Asset Management's ADMS Position: Q1 2020 in Review

Oxford Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2020, closing a stake of 218,701 shares — an estimated $829K sold.

Oxford Asset Management first reported a position in ADMS in Q2 2018 and held it in 4 quarters. The position peaked at $968K in Q3 2018. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2020.

  • Oxford Asset Management reported no remaining Adamas Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 218,701 Adamas Pharmaceuticals shares in Q1 2020, an estimated $829K.
  • Oxford Asset Management first reported a position in Adamas Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Oxford Asset Management's Adamas Pharmaceuticals position peaked at $968K in Q3 2018.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.